9 METERS BIOPHARMA, INC.

$ Overview Financials Valuation SEC Filings Company Website

2020 Q4 Form 10-Q Financial Statement

#000155198620000302 Filed on November 09, 2020

Income Statement

Concept	2020 Q4	2020 Q3	2019 Q4

Balance Sheet

Concept	2020 Q4	2020 Q3	2019 Q4
SHORT-TERM ASSETS
Cash & Short-Term Investments	$37.85M	$12.44M	$4.590M
YoY Change	724.62%	40.41%	-19.9%
Cash & Equivalents	$37.85M	$12.44M	$4.593M
Short-Term Investments
Other Short-Term Assets	$1.080M	$1.200M	$640.0K
YoY Change	68.75%	39.53%	-5.88%
Inventory
Prepaid Expenses
Receivables
Other Receivables
Total Short-Term Assets	$38.93M	$13.63M	$5.223M
YoY Change	645.3%	40.26%	-18.56%
LONG-TERM ASSETS
Property, Plant & Equipment	$11.19K	$44.97K	$25.42K
YoY Change	-55.98%	57.96%	-27.56%
Goodwill
YoY Change
Intangibles
YoY Change
Long-Term Investments
YoY Change
Other Assets	$5.580K	$5.580K	$5.580K
YoY Change	0.0%	0.0%	0.0%
Total Long-Term Assets	$231.5K	$276.5K	$73.83K
YoY Change	213.6%	206.1%	81.52%
TOTAL ASSETS
Total Short-Term Assets	$38.93M	$13.63M	$5.223M
Total Long-Term Assets	$231.5K	$276.5K	$73.83K
Total Assets	$39.16M	$13.91M	$5.297M
YoY Change	639.28%	41.79%	-17.93%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable	$1.488M	$2.565M	$3.890M
YoY Change	-61.75%	-16.11%	7.5%
Accrued Expenses	$5.290M	$6.067M	$4.748M
YoY Change	11.42%	225.63%	474.56%
Deferred Revenue
YoY Change
Short-Term Debt	$10.00K	$1.270M	$3.180M
YoY Change	-99.69%	-67.27%	-38.85%
Long-Term Debt Due
YoY Change
Total Short-Term Liabilities	$6.848M	$10.11M	$14.91M
YoY Change	-54.07%	-22.98%	47.44%
LONG-TERM LIABILITIES
Long-Term Debt	$0.00	$0.00	$0.00
YoY Change
Other Long-Term Liabilities	$170.0K	$180.0K
YoY Change
Total Long-Term Liabilities	$170.0K	$180.0K	$0.00
YoY Change
TOTAL LIABILITIES
Total Short-Term Liabilities	$6.848M	$10.11M	$14.91M
Total Long-Term Liabilities	$170.0K	$180.0K	$0.00
Total Liabilities	$7.016M	$10.29M	$14.91M
YoY Change	-52.94%	-21.64%	47.44%
SHAREHOLDERS EQUITY
Retained Earnings	-$132.1M	-$127.1M	-$70.56M
YoY Change	87.15%	106.13%	62.16%
Common Stock	$20.46K	$14.96K	$3.948K
YoY Change	418.31%	316.8%	51.32%
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity	$32.14M	$3.621M	-$9.614M
YoY Change
Total Liabilities & Shareholders Equity	$39.16M	$13.91M	$5.297M
YoY Change	639.28%	41.79%	-17.93%

Cashflow Statement

Concept	2020 Q4	2020 Q3	2019 Q4

Facts In Submission

Frame	Concept Type	Concept / XBRL Key	Value	Unit
	us-gaap	Operating Lease Cost OperatingLeaseCost	48000	USD
	us-gaap	Operating Income Loss OperatingIncomeLoss	-56102309	USD
CY2019Q3	us-gaap	Operating Lease Cost OperatingLeaseCost	15000	USD
	us-gaap	Operating Lease Cost OperatingLeaseCost	45000	USD
CY2020Q3	us-gaap	Operating Lease Cost OperatingLeaseCost	18000	USD
CY2020Q3	us-gaap	Operating Lease Liability OperatingLeaseLiability	227844	USD
CY2020Q3	us-gaap	Operating Lease Liability OperatingLeaseLiability	233206	USD
CY2019Q4	us-gaap	Operating Lease Liability Current OperatingLeaseLiabilityCurrent	42830	USD
CY2020Q3	us-gaap	Operating Lease Liability Current OperatingLeaseLiabilityCurrent	47199	USD
CY2019Q4	us-gaap	Operating Lease Liability Noncurrent OperatingLeaseLiabilityNoncurrent	0	USD
CY2020Q3	us-gaap	Operating Lease Liability Noncurrent OperatingLeaseLiabilityNoncurrent	180645	USD
	us-gaap	Operating Lease Payments OperatingLeasePayments	100000	USD
CY2019Q4	us-gaap	Operating Lease Right Of Use Asset OperatingLeaseRightOfUseAsset	42830	USD
CY2020Q3	us-gaap	Operating Lease Right Of Use Asset OperatingLeaseRightOfUseAsset	225924	USD
CY2020Q3	us-gaap	Operating Lease Right Of Use Asset OperatingLeaseRightOfUseAsset	233206	USD
CY2017Q4	us-gaap	Operating Lease Weighted Average Discount Rate Percent OperatingLeaseWeightedAverageDiscountRatePercent	0.12
	us-gaap	Research And Development In Process ResearchAndDevelopmentInProcess	0	USD
CY2020Q3	us-gaap	Research And Development In Process ResearchAndDevelopmentInProcess	0	USD
	us-gaap	Research And Development In Process ResearchAndDevelopmentInProcess	32266893	USD
CY2019Q4	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-70564778	USD
CY2020Q3	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-127098652	USD
CY2019Q1	us-gaap	Sale Of Stock Number Of Shares Issued In Transaction SaleOfStockNumberOfSharesIssuedInTransaction	4181068	shares
CY2019Q2	us-gaap	Sale Of Stock Number Of Shares Issued In Transaction SaleOfStockNumberOfSharesIssuedInTransaction	4318272	shares
CY2017Q4	us-gaap	Security Deposit SecurityDeposit	5000	USD
CY2020Q3	us-gaap	Stockholders Equity StockholdersEquity	3620575	USD
CY2019Q2	us-gaap	Warrants And Rights Outstanding Term WarrantsAndRightsOutstandingTerm	P5Y
CY2019Q3	us-gaap	Weighted Average Number Of Share Outstanding Basic And Diluted WeightedAverageNumberOfShareOutstandingBasicAndDiluted	35883953	shares
	us-gaap	Weighted Average Number Of Share Outstanding Basic And Diluted WeightedAverageNumberOfShareOutstandingBasicAndDiluted	32401624	shares
CY2020Q3	us-gaap	Weighted Average Number Of Share Outstanding Basic And Diluted WeightedAverageNumberOfShareOutstandingBasicAndDiluted	141625796	shares
	us-gaap	Weighted Average Number Of Share Outstanding Basic And Diluted WeightedAverageNumberOfShareOutstandingBasicAndDiluted	87323241	shares
	us-gaap	Severance Costs1 SeveranceCosts1	300000	USD
	us-gaap	Severance Costs1 SeveranceCosts1	800000	USD
	us-gaap	Share Based Compensation ShareBasedCompensation	2278000	USD
	us-gaap	Share Based Compensation ShareBasedCompensation	4499000	USD
CY2019Q1	us-gaap	Shares Issued Price Per Share SharesIssuedPricePerShare	2.33
CY2019Q4	us-gaap	Other Accrued Liabilities Current OtherAccruedLiabilitiesCurrent	30150	USD
CY2020Q3	us-gaap	Other Accrued Liabilities Current OtherAccruedLiabilitiesCurrent	265246	USD
CY2019Q4	us-gaap	Other Assets Noncurrent OtherAssetsNoncurrent	5580	USD
CY2020Q3	us-gaap	Other Assets Noncurrent OtherAssetsNoncurrent	5580	USD
	us-gaap	Payments Of Debt Issuance Costs PaymentsOfDebtIssuanceCosts	57000	USD
	us-gaap	Payments Of Debt Issuance Costs PaymentsOfDebtIssuanceCosts	23000	USD
	us-gaap	Payments Of Stock Issuance Costs PaymentsOfStockIssuanceCosts	1045468	USD
	us-gaap	Payments Of Stock Issuance Costs PaymentsOfStockIssuanceCosts	3962852	USD
	us-gaap	Payments To Acquire In Process Research And Development PaymentsToAcquireInProcessResearchAndDevelopment	0	USD
CY2020Q2	us-gaap	Stock Issued During Period Value New Issues StockIssuedDuringPeriodValueNewIssues	28754026	USD
CY2020Q3	us-gaap	Stock Issued During Period Value New Issues StockIssuedDuringPeriodValueNewIssues	2459583	USD
	us-gaap	Payments To Acquire In Process Research And Development PaymentsToAcquireInProcessResearchAndDevelopment	3184454	USD
	us-gaap	Payments To Acquire Property Plant And Equipment PaymentsToAcquirePropertyPlantAndEquipment	9475	USD
	us-gaap	Payments To Acquire Property Plant And Equipment PaymentsToAcquirePropertyPlantAndEquipment	2543	USD
CY2019Q4	us-gaap	Preferred Stock Par Or Stated Value Per Share PreferredStockParOrStatedValuePerShare	0.0001
CY2020Q3	us-gaap	Preferred Stock Par Or Stated Value Per Share PreferredStockParOrStatedValuePerShare	0.0001
CY2020Q2	us-gaap	Preferred Stock Par Or Stated Value Per Share PreferredStockParOrStatedValuePerShare	0.0001
CY2019Q4	us-gaap	Preferred Stock Shares Authorized PreferredStockSharesAuthorized	10000000	shares
CY2019Q1	us-gaap	Stock Issued During Period Value Restricted Stock Award Net Of Forfeitures StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures	0	USD
CY2019Q2	us-gaap	Stock Issued During Period Value Restricted Stock Award Net Of Forfeitures StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures	0	USD
CY2020Q2	us-gaap	Stock Issued During Period Value Restricted Stock Award Net Of Forfeitures StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures	0	USD
CY2020Q3	us-gaap	Preferred Stock Shares Authorized PreferredStockSharesAuthorized	10000000	shares
CY2020Q2	us-gaap	Preferred Stock Shares Authorized PreferredStockSharesAuthorized	600000	shares
CY2019Q4	us-gaap	Preferred Stock Shares Issued PreferredStockSharesIssued	0	shares
CY2020Q3	us-gaap	Preferred Stock Shares Issued PreferredStockSharesIssued	0	shares
CY2019Q4	us-gaap	Preferred Stock Shares Outstanding PreferredStockSharesOutstanding	0	shares
CY2020Q3	us-gaap	Preferred Stock Shares Outstanding PreferredStockSharesOutstanding	0	shares
CY2019Q4	us-gaap	Preferred Stock Value PreferredStockValue	0	USD
CY2020Q3	us-gaap	Preferred Stock Value PreferredStockValue	0	USD
CY2020Q2	us-gaap	Preferred Stock Value PreferredStockValue	12500000	USD
CY2019Q4	us-gaap	Prepaid Expense And Other Assets Current PrepaidExpenseAndOtherAssetsCurrent	555052	USD
CY2019Q2	us-gaap	Stock Issued During Period Value Stock Options Exercised StockIssuedDuringPeriodValueStockOptionsExercised	30064	USD
CY2018Q4	us-gaap	Stockholders Equity StockholdersEquity	-3659064	USD
CY2020Q3	us-gaap	Prepaid Expense And Other Assets Current PrepaidExpenseAndOtherAssetsCurrent	1122196	USD
CY2020Q2	us-gaap	Proceeds From Issuance Of Common Stock ProceedsFromIssuanceOfCommonStock	1200000	USD
	us-gaap	Proceeds From Issuance Of Common Stock ProceedsFromIssuanceOfCommonStock	20706919	USD
	us-gaap	Proceeds From Issuance Of Common Stock ProceedsFromIssuanceOfCommonStock	2370012	USD
CY2020Q2	us-gaap	Proceeds From Issuance Of Preferred Stock Preference Stock And Warrants ProceedsFromIssuanceOfPreferredStockPreferenceStockAndWarrants	22600000	USD
	us-gaap	Proceeds From Issuance Of Preferred Stock Preference Stock And Warrants ProceedsFromIssuanceOfPreferredStockPreferenceStockAndWarrants	0	USD
	us-gaap	Proceeds From Issuance Of Preferred Stock Preference Stock And Warrants ProceedsFromIssuanceOfPreferredStockPreferenceStockAndWarrants	22560994	USD
CY2020Q2	us-gaap	Proceeds From Issuance Of Warrants ProceedsFromIssuanceOfWarrants	1200000	USD
CY2019Q1	us-gaap	Proceeds From Issuance Or Sale Of Equity ProceedsFromIssuanceOrSaleOfEquity	9700000	USD
CY2019Q2	us-gaap	Proceeds From Issuance Or Sale Of Equity ProceedsFromIssuanceOrSaleOfEquity	7900000	USD
	us-gaap	Proceeds From Notes Payable ProceedsFromNotesPayable	5000000	USD
	us-gaap	Proceeds From Notes Payable ProceedsFromNotesPayable	2500000	USD
	us-gaap	Proceeds From Stock Options Exercised ProceedsFromStockOptionsExercised	30064	USD
	us-gaap	Proceeds From Stock Options Exercised ProceedsFromStockOptionsExercised	0	USD
	us-gaap	Proceeds From Warrant Exercises ProceedsFromWarrantExercises	0	USD
	us-gaap	Proceeds From Warrant Exercises ProceedsFromWarrantExercises	2045988	USD
CY2019Q1	us-gaap	Stockholders Equity StockholdersEquity	1617607	USD
CY2019Q2	us-gaap	Stockholders Equity StockholdersEquity	5006309	USD
CY2019Q3	us-gaap	Stockholders Equity StockholdersEquity	-3314923	USD
CY2019Q4	us-gaap	Stockholders Equity StockholdersEquity	-9614014	USD
CY2020Q1	us-gaap	Stockholders Equity StockholdersEquity	-12550176	USD
CY2020Q2	us-gaap	Stockholders Equity StockholdersEquity	3067286	USD
CY2019Q4	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	25422	USD
	us-gaap	Repayments Of Debt RepaymentsOfDebt	1469804	USD
CY2019Q3	us-gaap	Research And Development Expense Excluding Acquired In Process Cost ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost	3943420	USD
CY2020Q3	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	44966	USD
	us-gaap	Repayments Of Debt RepaymentsOfDebt	6745833	USD
	us-gaap	Research And Development Expense Excluding Acquired In Process Cost ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost	8215079	USD
CY2020Q3	us-gaap	Research And Development Expense Excluding Acquired In Process Cost ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost	4413707	USD
	us-gaap	Research And Development Expense Excluding Acquired In Process Cost ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost	7457509	USD
CY2019Q3	us-gaap	Research And Development In Process ResearchAndDevelopmentInProcess	0	USD
CY2019Q2	us-gaap	Shares Issued Price Per Share SharesIssuedPricePerShare	2.025
CY2020Q2	us-gaap	Stock And Warrants Issued During Period Value Preferred Stock And Warrants StockAndWarrantsIssuedDuringPeriodValuePreferredStockAndWarrants	22560994	USD
	us-gaap	Stock Issued1 StockIssued1	0	USD
	us-gaap	Stock Issued1 StockIssued1	4142977	USD
CY2020Q2	us-gaap	Stock Issued During Period Shares New Issues StockIssuedDuringPeriodSharesNewIssues	12230418	shares
CY2020Q2	us-gaap	Stock Issued During Period Value Conversion Of Convertible Securities StockIssuedDuringPeriodValueConversionOfConvertibleSecurities	0	USD
CY2019Q1	us-gaap	Stock Issued During Period Value New Issues StockIssuedDuringPeriodValueNewIssues	11475255	USD
CY2019Q2	us-gaap	Stock Issued During Period Value New Issues StockIssuedDuringPeriodValueNewIssues	8744501	USD
	nmtr	Convertible Promissory Notesbeneficial Conversion Feature ConvertiblePromissoryNotesbeneficialConversionFeature	2110860	USD
	us-gaap	Number Of Operating Segments NumberOfOperatingSegments	1	segment
CY2019Q3	us-gaap	Operating Expenses OperatingExpenses	6507928	USD
	us-gaap	Operating Expenses OperatingExpenses	16943793	USD
CY2020Q3	us-gaap	Operating Expenses OperatingExpenses	6304199	USD
	us-gaap	Operating Expenses OperatingExpenses	56102309	USD
CY2019Q3	us-gaap	Operating Income Loss OperatingIncomeLoss	-6507928	USD
	us-gaap	Operating Income Loss OperatingIncomeLoss	-16943793	USD
CY2020Q3	us-gaap	Operating Income Loss OperatingIncomeLoss	-6304199	USD
CY2019Q3	nmtr	Accrued Milestone Fees AccruedMilestoneFees	300000	USD
	nmtr	Accrued Milestone Fees AccruedMilestoneFees	300000	USD
CY2020Q3	nmtr	Accrued Milestone Fees AccruedMilestoneFees	2200000	USD
CY2019Q1	nmtr	Adjustments To Additional Paid In Capital Allocation Of Warrants To Liabilities AdjustmentsToAdditionalPaidInCapitalAllocationOfWarrantsToLiabilities	1970000	USD
CY2019Q2	nmtr	Adjustments To Additional Paid In Capital Allocation Of Warrants To Liabilities AdjustmentsToAdditionalPaidInCapitalAllocationOfWarrantsToLiabilities	1360000	USD
CY2020Q2	nmtr	Adjustments To Additional Paid In Capital Warrants Exercised AdjustmentsToAdditionalPaidInCapitalWarrantsExercised	1219001	USD
CY2020Q3	nmtr	Adjustments To Additional Paid In Capital Warrants Exercised AdjustmentsToAdditionalPaidInCapitalWarrantsExercised	826987	USD
CY2020Q2	nmtr	Adjustmentsto Additional Paidin Capital Warrant Inducement Expense AdjustmentstoAdditionalPaidinCapitalWarrantInducementExpense	6467048	USD
	dei	Current Fiscal Year End Date CurrentFiscalYearEndDate	--12-31
CY2020Q3	nmtr	Capital Stock Authorized CapitalStockAuthorized	360000000	shares
	nmtr	Asset Acquisition Research And Development In Process AssetAcquisitionResearchAndDevelopmentInProcess	0	USD
	nmtr	Asset Acquisition Research And Development In Process AssetAcquisitionResearchAndDevelopmentInProcess	28754026	USD
	dei	Amendment Flag AmendmentFlag	false
	dei	Document Fiscal Period Focus DocumentFiscalPeriodFocus	Q3
CY2019Q4	nmtr	Class Of Warrant Or Right Number Of Shares Issued Per Warrant ClassOfWarrantOrRightNumberOfSharesIssuedPerWarrant	1.2	shares
CY2019Q2	nmtr	Class Of Warrant Or Right Purchase Price Of Each Additional Warrant ClassOfWarrantOrRightPurchasePriceOfEachAdditionalWarrant	0.125
CY2019Q2	nmtr	Class Of Warrant Or Right Restriction Period ClassOfWarrantOrRightRestrictionPeriod	P45D
CY2020Q2	nmtr	Convertible Preferred Stock Beneficial Conversion Feature ConvertiblePreferredStockBeneficialConversionFeature	3100000	USD
	nmtr	Convertible Promissory Notesbeneficial Conversion Feature ConvertiblePromissoryNotesbeneficialConversionFeature	0	USD
	nmtr	Accrued Milestone Fees AccruedMilestoneFees	2200000	USD
CY2020Q3	nmtr	Accrued Severance Costs AccruedSeveranceCosts	400000	USD
	dei	Document Fiscal Year Focus DocumentFiscalYearFocus	2020
	dei	Document Period End Date DocumentPeriodEndDate	2020-09-30
	dei	Document Type DocumentType	10-Q
	dei	Entity Central Index Key EntityCentralIndexKey	0001551986
CY2020Q4	dei	Entity Common Stock Shares Outstanding EntityCommonStockSharesOutstanding	150324757	shares
	dei	Entity Current Reporting Status EntityCurrentReportingStatus	Yes
	dei	Entity Emerging Growth Company EntityEmergingGrowthCompany	true
	dei	Entity Ex Transition Period EntityExTransitionPeriod	true
	dei	Entity Filer Category EntityFilerCategory	Non-accelerated Filer
	dei	Entity Interactive Data Current EntityInteractiveDataCurrent	Yes
	dei	Entity Registrant Name EntityRegistrantName	9 METERS BIOPHARMA, INC.
	dei	Entity Shell Company EntityShellCompany	false
	dei	Entity Small Business EntitySmallBusiness	true
CY2019Q4	nmtr	Accrued Clinical Expenses Current AccruedClinicalExpensesCurrent	4143269	USD
CY2020Q3	nmtr	Accrued Clinical Expenses Current AccruedClinicalExpensesCurrent	4591044	USD
CY2020Q2	nmtr	Convertible Promissory Notesbeneficial Conversion Feature ConvertiblePromissoryNotesbeneficialConversionFeature	-207632	USD
CY2020Q3	nmtr	Convertible Promissory Notesbeneficial Conversion Feature ConvertiblePromissoryNotesbeneficialConversionFeature	-1903228	USD
CY2018Q3	nmtr	Estimated Clinical Trial Data Management Fee EstimatedClinicalTrialDataManagementFee	1100000	USD
	nmtr	Gain Losson Extinguishmentof Derivative Liability GainLossonExtinguishmentofDerivativeLiability	370000	USD
	nmtr	Gain Losson Extinguishmentof Derivative Liability GainLossonExtinguishmentofDerivativeLiability	0	USD
CY2017Q4	nmtr	Lessee Operating Lease Term Of Payments LesseeOperatingLeaseTermOfPayments	P24M
	nmtr	Non Cash Issuance Of Common Stock With Merger NonCashIssuanceOfCommonStockWithMerger	0	USD
	nmtr	Non Cash Issuance Of Common Stock With Merger NonCashIssuanceOfCommonStockWithMerger	28754026	USD
	nmtr	Noncash Addition Of Deferred Offering Costs NoncashAdditionOfDeferredOfferingCosts	151137	USD
	nmtr	Noncash Addition Of Deferred Offering Costs NoncashAdditionOfDeferredOfferingCosts	0	USD
	nmtr	Noncash Addition Of Derivative Liability NoncashAdditionOfDerivativeLiability	1281000	USD
	nmtr	Noncash Addition Of Derivative Liability NoncashAdditionOfDerivativeLiability	370000	USD
CY2020Q2	nmtr	Number Of Amended And Restated License Agreements NumberOfAmendedAndRestatedLicenseAgreements	2	license_agreement
CY2020Q3	nmtr	Number Of Stock Option Plans NumberOfStockOptionPlans	2	plan
CY2017Q4	nmtr	Operating Lease Annual Rental Payments OperatingLeaseAnnualRentalPayments	60000	USD
CY2020Q3	nmtr	Operating Lease Annual Rental Payments OperatingLeaseAnnualRentalPayments	72000	USD
CY2017Q4	nmtr	Operating Lease Monthly Rental Payments OperatingLeaseMonthlyRentalPayments	5000	USD
CY2020Q3	nmtr	Operating Lease Monthly Rental Payments OperatingLeaseMonthlyRentalPayments	6000	USD
CY2020Q2	nmtr	Preferred Stock Warrant Value PreferredStockWarrantValue	7000000	USD
CY2020Q2	nmtr	Proceeds From Issuance Of Preferred Stock Preference Stock And Warrants Net ProceedsFromIssuanceOfPreferredStockPreferenceStockAndWarrantsNet	19200000	USD
CY2020Q2	nmtr	Proceeds From Warrant Exercises And Issuance Of Common Stock ProceedsFromWarrantExercisesAndIssuanceOfCommonStock	4300000	USD
CY2014	nmtr	Royalties Payment Expiration Requirement RoyaltiesPaymentExpirationRequirement	P10Y
CY2018Q3	nmtr	Saleof Stock Shelf Registration Maximum Equity Offering Price SaleofStockShelfRegistrationMaximumEquityOfferingPrice	200000000	USD
	nmtr	Severance Costs Equal Installment Period SeveranceCostsEqualInstallmentPeriod	P12M
	nmtr	Severance Provisions Annual Base Salary Period SeveranceProvisionsAnnualBaseSalaryPeriod	P12M
	nmtr	Severance Provisions Continuation Of Health Insurance Benefits Period SeveranceProvisionsContinuationOfHealthInsuranceBenefitsPeriod	P12M
CY2019Q4	nmtr	Stock Issued During Period Shares Exerciseof Warrants StockIssuedDuringPeriodSharesExerciseofWarrants	3593714.4	shares
	nmtr	Stock Issued During Period Shares Exerciseof Warrants StockIssuedDuringPeriodSharesExerciseofWarrants	1847309	shares
	nmtr	Stock Issued During Period Shares Exerciseof Warrants StockIssuedDuringPeriodSharesExerciseofWarrants	1847309	shares
CY2020Q2	nmtr	Stock Issued During Period Shares Warrants Exercised StockIssuedDuringPeriodSharesWarrantsExercised	12230418	shares
CY2020Q1	nmtr	Stock Issued During Period Value Warrant Exchange StockIssuedDuringPeriodValueWarrantExchange	690839	USD
CY2019Q3	nmtr	Warrant Inducement Expense WarrantInducementExpense	0	USD
	nmtr	Warrant Inducement Expense WarrantInducementExpense	0	USD
CY2020Q3	nmtr	Warrant Inducement Expense WarrantInducementExpense	0	USD
	nmtr	Warrant Inducement Expense WarrantInducementExpense	7200000	USD
	nmtr	Warrant Inducement Expense WarrantInducementExpense	7157887	USD
CY2019Q4	nmtr	Warrant Liability Current WarrantLiabilityCurrent	2637500	USD
CY2020Q3	nmtr	Warrant Liability Current WarrantLiabilityCurrent	0	USD
CY2020Q3	nmtr	Warrants Accumulated Gross Unrealized Gain WarrantsAccumulatedGrossUnrealizedGain	1815200	USD
CY2019Q2	nmtr	Warrants And Rights Outstanding Exercise Commencement Period WarrantsAndRightsOutstandingExerciseCommencementPeriod	P6M
	nmtr	Writeoff Of Deferred Offering Costs WriteoffOfDeferredOfferingCosts	100056	USD
	nmtr	Writeoff Of Deferred Offering Costs WriteoffOfDeferredOfferingCosts	0	USD
CY2019Q4	us-gaap	Accounts Payable Current AccountsPayableCurrent	3890094	USD
CY2020Q3	us-gaap	Accounts Payable Current AccountsPayableCurrent	2564565	USD
CY2019Q4	us-gaap	Accrued Liabilities Current AccruedLiabilitiesCurrent	4747751	USD
CY2020Q3	us-gaap	Accrued Liabilities Current AccruedLiabilitiesCurrent	6067217	USD
CY2019Q4	us-gaap	Additional Paid In Capital AdditionalPaidInCapital	60946816	USD
CY2020Q3	us-gaap	Additional Paid In Capital AdditionalPaidInCapital	130704268	USD
	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	2278000	USD
	us-gaap	Amortization Of Debt Discount Premium AmortizationOfDebtDiscountPremium	713709	USD
	us-gaap	Amortization Of Debt Discount Premium AmortizationOfDebtDiscountPremium	1288098	USD
CY2020Q3	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	202000	USD
	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	4499000	USD
CY2020Q3	us-gaap	Adjustments To Additional Paid In Capital Stock Issued Issuance Costs AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts	73149	USD
CY2019Q3	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	900000	USD
CY2020Q2	us-gaap	Adjustments To Additional Paid In Capital Convertible Debt With Conversion Feature AdjustmentsToAdditionalPaidInCapitalConvertibleDebtWithConversionFeature	575000	USD
CY2020Q3	us-gaap	Adjustments To Additional Paid In Capital Convertible Debt With Conversion Feature AdjustmentsToAdditionalPaidInCapitalConvertibleDebtWithConversionFeature	3567977	USD
CY2019Q1	us-gaap	Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue	526000	USD
CY2019Q2	us-gaap	Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue	852000	USD
CY2019Q3	us-gaap	Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue	900000	USD
CY2020Q1	us-gaap	Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue	276000	USD
CY2020Q2	us-gaap	Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue	4021000	USD
CY2020Q3	us-gaap	Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue	202000	USD
CY2019Q1	us-gaap	Adjustments To Additional Paid In Capital Stock Issued Issuance Costs AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts	319819	USD
CY2019Q2	us-gaap	Adjustments To Additional Paid In Capital Stock Issued Issuance Costs AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts	389623	USD
CY2020Q1	us-gaap	Adjustments To Additional Paid In Capital Stock Issued Issuance Costs AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts	300000	USD
CY2020Q2	us-gaap	Adjustments To Additional Paid In Capital Stock Issued Issuance Costs AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts	3589703	USD
	us-gaap	Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount	25571927	shares
	us-gaap	Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount	25600000	shares
	us-gaap	Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount	57100000	shares
	us-gaap	Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount	57114096	shares
CY2019Q4	us-gaap	Assets Assets	5296816	USD
CY2020Q3	us-gaap	Assets Assets	13909648	USD
CY2019Q4	us-gaap	Assets Current AssetsCurrent	5222984	USD
CY2020Q3	us-gaap	Assets Current AssetsCurrent	13633178	USD
CY2019Q4	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	4592932	USD
CY2020Q3	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	12435982	USD
CY2018Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	5728900	USD
CY2019Q3	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	8863796	USD
CY2019Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	4592932	USD
CY2020Q3	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	12435982	USD
	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect	3134896	USD
	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect	7843050	USD
CY2019Q4	us-gaap	Certificates Of Deposit At Carrying Value CertificatesOfDepositAtCarryingValue	75000	USD
CY2020Q3	us-gaap	Certificates Of Deposit At Carrying Value CertificatesOfDepositAtCarryingValue	75000	USD
CY2019Q2	us-gaap	Class Of Warrant Or Right Exercise Price Of Warrants Or Rights1 ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1	2.13
CY2020Q2	us-gaap	Class Of Warrant Or Right Exercise Price Of Warrants Or Rights1 ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1	0.10
CY2019Q2	us-gaap	Class Of Warrant Or Right Number Of Securities Called By Each Warrant Or Right ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight	3897010	shares
CY2019Q4	us-gaap	Commitments And Contingencies CommitmentsAndContingencies		USD
CY2020Q3	us-gaap	Commitments And Contingencies CommitmentsAndContingencies		USD
CY2019Q4	us-gaap	Common Stock Capital Shares Reserved For Future Issuance CommonStockCapitalSharesReservedForFutureIssuance	25141814	shares
CY2020Q3	us-gaap	Common Stock Capital Shares Reserved For Future Issuance CommonStockCapitalSharesReservedForFutureIssuance	67443081	shares
CY2019Q4	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.0001
CY2020Q3	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.0001
CY2020Q1	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.0001
CY2019Q4	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	350000000	shares
CY2020Q3	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	350000000	shares
CY2019Q4	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	39477667	shares
CY2020Q3	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	149575457	shares
CY2019Q4	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	39477667	shares
CY2020Q3	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	149575457	shares
CY2019Q4	us-gaap	Common Stock Value CommonStockValue	3948	USD
CY2020Q3	us-gaap	Common Stock Value CommonStockValue	14959	USD
CY2019Q4	us-gaap	Convertible Notes Payable Current ConvertibleNotesPayableCurrent	3184655	USD
CY2020Q3	us-gaap	Convertible Notes Payable Current ConvertibleNotesPayableCurrent	1265020	USD
	us-gaap	Depreciation Depreciation	16104	USD
	us-gaap	Depreciation Depreciation	16883	USD
CY2019Q3	us-gaap	Derivative Gain Loss On Derivative Net DerivativeGainLossOnDerivativeNet	229000	USD
	us-gaap	Derivative Gain Loss On Derivative Net DerivativeGainLossOnDerivativeNet	881000	USD
CY2020Q3	us-gaap	Derivative Gain Loss On Derivative Net DerivativeGainLossOnDerivativeNet	86000	USD
	us-gaap	Derivative Gain Loss On Derivative Net DerivativeGainLossOnDerivativeNet	617000	USD
CY2019Q4	us-gaap	Derivative Liabilities Current DerivativeLiabilitiesCurrent	408000	USD
CY2020Q3	us-gaap	Derivative Liabilities Current DerivativeLiabilitiesCurrent	161000	USD
CY2019Q3	us-gaap	Earnings Per Share Basic And Diluted EarningsPerShareBasicAndDiluted	-0.26
	us-gaap	Earnings Per Share Basic And Diluted EarningsPerShareBasicAndDiluted	-0.56
CY2020Q3	us-gaap	Earnings Per Share Basic And Diluted EarningsPerShareBasicAndDiluted	-0.06
	us-gaap	Earnings Per Share Basic And Diluted EarningsPerShareBasicAndDiluted	-0.65
CY2019Q4	us-gaap	Employee Related Liabilities Current EmployeeRelatedLiabilitiesCurrent	574332	USD
CY2020Q3	us-gaap	Employee Related Liabilities Current EmployeeRelatedLiabilitiesCurrent	1210927	USD
CY2019Q3	us-gaap	Fair Value Adjustment Of Warrants FairValueAdjustmentOfWarrants	2500000	USD
CY2019Q3	us-gaap	Fair Value Adjustment Of Warrants FairValueAdjustmentOfWarrants	2528100	USD
	us-gaap	Fair Value Adjustment Of Warrants FairValueAdjustmentOfWarrants	-141700	USD
	us-gaap	Fair Value Adjustment Of Warrants FairValueAdjustmentOfWarrants	-100000	USD
CY2020Q3	us-gaap	Fair Value Adjustment Of Warrants FairValueAdjustmentOfWarrants	0	USD
	us-gaap	Fair Value Adjustment Of Warrants FairValueAdjustmentOfWarrants	-2637500	USD
	us-gaap	Fair Value Liabilities Measured On Recurring Basis Change In Unrealized Gain Loss FairValueLiabilitiesMeasuredOnRecurringBasisChangeInUnrealizedGainLoss	617000	USD
CY2019Q4	us-gaap	Fair Value Measurement With Unobservable Inputs Reconciliations Recurring Basis Liability Value FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue	3045500	USD
CY2020Q3	us-gaap	Fair Value Measurement With Unobservable Inputs Reconciliations Recurring Basis Liability Value FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue	161000	USD
	us-gaap	Gain Loss On Sale Of Property Plant Equipment GainLossOnSaleOfPropertyPlantEquipment	0	USD
	us-gaap	Gain Loss On Sale Of Property Plant Equipment GainLossOnSaleOfPropertyPlantEquipment	-7031	USD
CY2019Q3	us-gaap	Gains Losses On Extinguishment Of Debt GainsLossesOnExtinguishmentOfDebt	0	USD
	us-gaap	Gains Losses On Extinguishment Of Debt GainsLossesOnExtinguishmentOfDebt	-1049166	USD
	us-gaap	Gains Losses On Extinguishment Of Debt GainsLossesOnExtinguishmentOfDebt	-1000000	USD
CY2020Q3	us-gaap	Gains Losses On Extinguishment Of Debt GainsLossesOnExtinguishmentOfDebt	0	USD
	us-gaap	Gains Losses On Extinguishment Of Debt GainsLossesOnExtinguishmentOfDebt	0	USD
CY2019Q3	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	2564508	USD
	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	8728714	USD
CY2020Q3	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	1890492	USD
	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	9220020	USD
CY2019Q3	us-gaap	Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest	-9221232	USD
	us-gaap	Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest	-18144237	USD
CY2020Q3	us-gaap	Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest	-8333337	USD
	us-gaap	Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest	-56533874	USD
	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	0	USD
	us-gaap	Increase Decrease In Accounts Payable IncreaseDecreaseInAccountsPayable	-708219	USD
	us-gaap	Increase Decrease In Accounts Payable IncreaseDecreaseInAccountsPayable	-1388457	USD
CY2019Q3	us-gaap	Interest Income Other InterestIncomeOther	57848	USD
	us-gaap	Interest Income Other InterestIncomeOther	156945	USD
CY2019Q3	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	0	USD
	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	0	USD
CY2020Q3	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	0	USD
	us-gaap	Increase Decrease In Accrued Liabilities And Other Operating Liabilities IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities	1036898	USD
	us-gaap	Increase Decrease In Accrued Liabilities And Other Operating Liabilities IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities	4549153	USD
	us-gaap	Increase Decrease In Derivative Liabilities IncreaseDecreaseInDerivativeLiabilities	-511000	USD
	us-gaap	Increase Decrease In Derivative Liabilities IncreaseDecreaseInDerivativeLiabilities	-617000	USD
	us-gaap	Increase Decrease In Interest Payable Net IncreaseDecreaseInInterestPayableNet	-101624	USD
	us-gaap	Increase Decrease In Interest Payable Net IncreaseDecreaseInInterestPayableNet	3427	USD
	us-gaap	Increase Decrease In Prepaid Expense IncreaseDecreaseInPrepaidExpense	276185	USD
	us-gaap	Increase Decrease In Prepaid Expense IncreaseDecreaseInPrepaidExpense	498873	USD
CY2019Q3	us-gaap	Interest Expense InterestExpense	472052	USD
	us-gaap	Interest Expense InterestExpense	1330923	USD
CY2020Q3	us-gaap	Interest Expense InterestExpense	2118433	USD
	us-gaap	Interest Expense InterestExpense	3710725	USD
	us-gaap	Interest Expense Debt Excluding Amortization InterestExpenseDebtExcludingAmortization	314721	USD
	us-gaap	Interest Expense Debt Excluding Amortization InterestExpenseDebtExcludingAmortization	298048	USD
CY2020Q3	us-gaap	Interest Income Other InterestIncomeOther	3295	USD
	us-gaap	Interest Income Other InterestIncomeOther	24660	USD
	us-gaap	Interest Paid Net InterestPaidNet	418927	USD
	us-gaap	Interest Paid Net InterestPaidNet	54578	USD
CY2019Q4	us-gaap	Interest Payable Current InterestPayableCurrent	0	USD
CY2020Q3	us-gaap	Interest Payable Current InterestPayableCurrent	3427	USD
CY2020Q3	us-gaap	Lessee Operating Lease Liability Payments Due LesseeOperatingLeaseLiabilityPaymentsDue	288000	USD
CY2020Q3	us-gaap	Lessee Operating Lease Liability Payments Due Next Twelve Months LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths	72000	USD
CY2020Q3	us-gaap	Lessee Operating Lease Liability Payments Due Year Four LesseeOperatingLeaseLiabilityPaymentsDueYearFour	54000	USD
CY2020Q3	us-gaap	Lessee Operating Lease Liability Payments Due Year Three LesseeOperatingLeaseLiabilityPaymentsDueYearThree	72000	USD
CY2020Q3	us-gaap	Lessee Operating Lease Liability Payments Due Year Two LesseeOperatingLeaseLiabilityPaymentsDueYearTwo	72000	USD
CY2020Q3	us-gaap	Lessee Operating Lease Liability Payments Remainder Of Fiscal Year LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear	18000	USD
CY2020Q3	us-gaap	Lessee Operating Lease Liability Undiscounted Excess Amount LesseeOperatingLeaseLiabilityUndiscountedExcessAmount	60156	USD
CY2017Q4	us-gaap	Lessee Operating Lease Renewal Term LesseeOperatingLeaseRenewalTerm	P2Y
CY2020Q3	us-gaap	Lessee Operating Lease Renewal Term LesseeOperatingLeaseRenewalTerm	P3Y
CY2017Q4	us-gaap	Lessee Operating Lease Term Of Contract LesseeOperatingLeaseTermOfContract	P3Y
CY2020Q3	us-gaap	Lessee Operating Lease Term Of Contract LesseeOperatingLeaseTermOfContract	P4Y
CY2019Q4	us-gaap	Liabilities Liabilities	14910830	USD
CY2020Q3	us-gaap	Liabilities Liabilities	10289073	USD
CY2019Q4	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	5296816	USD
CY2020Q3	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	13909648	USD
CY2019Q4	us-gaap	Liabilities Current LiabilitiesCurrent	14910830	USD
CY2020Q3	us-gaap	Liabilities Current LiabilitiesCurrent	10108428	USD
CY2020Q3	us-gaap	Loss Contingency Accrual At Carrying Value LossContingencyAccrualAtCarryingValue	600000	USD
CY2020Q2	us-gaap	Loss Contingency Estimate Of Possible Loss LossContingencyEstimateOfPossibleLoss	1700000	USD
	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	17888682	USD
	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	24021338	USD
	us-gaap	Net Cash Provided By Used In Investing Activities NetCashProvidedByUsedInInvestingActivities	-9475	USD
	us-gaap	Net Cash Provided By Used In Investing Activities NetCashProvidedByUsedInInvestingActivities	-3186997	USD
	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	-14744311	USD
	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	-12991291	USD
CY2019Q1	us-gaap	Net Income Loss NetIncomeLoss	-4434765	USD
CY2019Q2	us-gaap	Net Income Loss NetIncomeLoss	-4488240	USD
CY2019Q3	us-gaap	Net Income Loss NetIncomeLoss	-9221232	USD
	us-gaap	Net Income Loss NetIncomeLoss	-18144237	USD
CY2020Q1	us-gaap	Net Income Loss NetIncomeLoss	-3603001	USD
CY2020Q2	us-gaap	Net Income Loss NetIncomeLoss	-44597536	USD
CY2020Q3	us-gaap	Net Income Loss NetIncomeLoss	-8333337	USD
	us-gaap	Net Income Loss NetIncomeLoss	-56533874	USD
CY2019Q3	us-gaap	Nonoperating Income Expense NonoperatingIncomeExpense	-2713304	USD
	us-gaap	Nonoperating Income Expense NonoperatingIncomeExpense	-1200444	USD
CY2020Q3	us-gaap	Nonoperating Income Expense NonoperatingIncomeExpense	-2029138	USD
	us-gaap	Nonoperating Income Expense NonoperatingIncomeExpense	-431565	USD
	us-gaap	Use Of Estimates UseOfEstimates	<div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">Use of Estimates</font></div><div style="line-height:120%;text-indent:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div><div style="line-height:120%;text-align:justify;text-indent:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The preparation of financial statements in conformity with U.S. GAAP requires management to make estimates and assumptions that affect the amounts reported in the financial statements and disclosures made in the accompanying notes to the financial statements. Areas of the financial statements where estimates may have the most significant effect include accrued expenses, share-based compensation, valuation of the derivative liability and warrant liabilities, valuation allowance for income tax assets, management’s estimate of the acquisition costs associated with acquired in-process research and development and management’s assessment of the Company’s ability to continue as a going concern. Changes in the facts or circumstances underlying these estimates could result in material changes and actual results could differ from these estimates.</font></div></div>

Files In Submission

Name	View Source	Status
0001551986-20-000302-index-headers.html	Edgar Link	pending
0001551986-20-000302-index.html	Edgar Link	pending
0001551986-20-000302.txt	Edgar Link	pending
0001551986-20-000302-xbrl.zip	Edgar Link	pending
ex311q32020.htm	Edgar Link	pending
ex312q32020.htm	Edgar Link	pending
ex321q32020.htm	Edgar Link	pending
ex322q32020.htm	Edgar Link	pending
FilingSummary.xml	Edgar Link	unprocessable
Financial_Report.xlsx	Edgar Link	pending
nmtr-20200930.xml	Edgar Link	completed
nmtr-20200930.xsd	Edgar Link	pending
nmtr-20200930_cal.xml	Edgar Link	unprocessable
nmtr-20200930_def.xml	Edgar Link	unprocessable
nmtr-20200930_lab.xml	Edgar Link	unprocessable
nmtr-20200930_pre.xml	Edgar Link	unprocessable
nmtrq3202010-q.htm	Edgar Link	pending
pipelinegraphic.jpg	Edgar Link	pending
R1.htm	Edgar Link	pending
R10.htm	Edgar Link	pending
R11.htm	Edgar Link	pending
R12.htm	Edgar Link	pending
R13.htm	Edgar Link	pending
R14.htm	Edgar Link	pending
R15.htm	Edgar Link	pending
R16.htm	Edgar Link	pending
R17.htm	Edgar Link	pending
R18.htm	Edgar Link	pending
R19.htm	Edgar Link	pending
R2.htm	Edgar Link	pending
R20.htm	Edgar Link	pending
R21.htm	Edgar Link	pending
R22.htm	Edgar Link	pending
R23.htm	Edgar Link	pending
R24.htm	Edgar Link	pending
R25.htm	Edgar Link	pending
R26.htm	Edgar Link	pending
R27.htm	Edgar Link	pending
R28.htm	Edgar Link	pending
R29.htm	Edgar Link	pending
R3.htm	Edgar Link	pending
R30.htm	Edgar Link	pending
R31.htm	Edgar Link	pending
R32.htm	Edgar Link	pending
R33.htm	Edgar Link	pending
R34.htm	Edgar Link	pending
R35.htm	Edgar Link	pending
R36.htm	Edgar Link	pending
R37.htm	Edgar Link	pending
R38.htm	Edgar Link	pending
R39.htm	Edgar Link	pending
R4.htm	Edgar Link	pending
R40.htm	Edgar Link	pending
R41.htm	Edgar Link	pending
R42.htm	Edgar Link	pending
R5.htm	Edgar Link	pending
R6.htm	Edgar Link	pending
R7.htm	Edgar Link	pending
R8.htm	Edgar Link	pending
R9.htm	Edgar Link	pending
report.css	Edgar Link	pending
Show.js	Edgar Link	pending

Create your account

Find Stocks Worth Researching

Deeply Understand Businesses

Value Businesses Intelligently

9 METERS BIOPHARMA, INC.

2020 Q4 Form 10-Q Financial Statement

#000155198620000302 Filed on November 09, 2020

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission